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ABSTRACT: The primary aim of this study was to identify structural features that alter the
intestinal epithelial permeability and efﬂux in a series of novel HIV-1 protease inhibitors (PIs).
Eleven PIs were selected containing a tertiary alcohol in a transition-state mimicking scaffold,
in which two substituents (R1 and R2) were varied systematically. Indinavir was selected as
a reference compound. The apical-to-basolateral permeability was investigated in 2/4/A1 and
Caco-2 monolayers. In addition, the basolateral-to-apical permeability was investigated in the
Caco-2 monolayers and the efﬂux ratios were calculated. The absence of active drug transport
processes in 2/4/A1 cells allowed identiﬁcation and modeling of structural elements affecting
the passive permeability. For instance, small aromatic R1 substituents and a small (bromo-) R2
substituent were associated with a high passive permeability. Efﬂux studies in Caco-2 cells indi-
catedthatamide-substitutedneutralhydrophobicaminoacids,suchasvalineandleucine,inthe
R1 position, reduced the apical-to-basolateral transport and enhanced the efﬂux. We conclude
that our investigation revealed structural features that alter the intestinal epithelial perme-
ability and efﬂux in the series of PIs and hope that these results can contribute to the synthesis
of PIs with improved permeability and limited efﬂux properties. © 2011 Wiley-Liss, Inc. and the
American Pharmacists Association J Pharm Sci 100:3763–3772, 2011
Keywords: Absorption; ADME; Caco-2 cells; Drug design; Drug transport; HIV/AIDS; In-
testinal absorption; Passive diffusion/transport; P-glycoprotein; Permeability
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bovine serum albumin; ECM, extracellular matrix; DMSO,
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1-piperazineethanesulfonic acid; Papp, apparent permeability
coefﬁcient; TEER, transepithelial electrical resistance; ABC trans-
porters, ATP-binding cassette transporters; LC–MS/MS, liquid
chromatography–tandem mass spectrometry; TPSA, topological
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coefﬁcient of unionized species, log D, calculated log distribution
coefﬁcient of unionized and ionized species in octanol–buffer (pH
7.4); PLS, the partial least-squares projection to latent structures;
Ki, binding afﬁnity (dissociation) constant; EC50, half maximal
effective concentration.
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INTRODUCTION
Drug absorption across the human intestinal wall
occurs predominantly via passive transcellular dif-
fusion. Also for many drugs that are substrates for
uptake and efﬂux of transport proteins in the intesti-
nal epithelium, passive transport often contributes
signiﬁcantly to the total transport, in particular at
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clinical doses.1 This simpliﬁes the predictions of in-
testinal drug permeability and absorption, as a result
of which fairly good predictions have been obtained
without the consideration of any active transport
mechanisms.2,3 One predictive model is 2/4/A1, a
conditionally immortalized rat intestinal epithelial
cell line that forms tight cell monolayers with a
permeability that is comparable to that of the hu-
man jejunum.4,5 When grown on permeable supports,
the permeability to registered drugs is quantitatively
comparable to that of the human intestine6,7 despite
the fact that 2/4/A1 cells do not have functional drug
transporting proteins such a P-glycoprotein (P-gp).8
However, whether this cell line would also prove to be
useful for permeability proﬁling in a drug discovery
setting had not, as yet, been investigated.
For some drug classes, including HIV-1 protease in-
hibitors (PIs), active transport mechanisms, such as
P-gp-mediated efﬂux, are common. The coexistence of
activeandpassivetransportmechanismsmaycompli-
cate both in vitro and in silico predictions of intesti-
nal permeability in models such as 2/4/A1. Caco-2 cell
monolayers represent the most commonly used cell
culture model for in vitro studies of intestinal perme-
ability, and they afford the opportunity to investigate
both passive and active transport processes.9–11 Caco-
2 monolayers express many active transport mecha-
nisms of the human small intestine, including func-
tionalefﬂuxproteins,suchasP-gp,andthereforethey
are commonly used to identify compounds with a high
drug efﬂux.12,13
Drug-like compounds in drug discovery settings
have not generally been optimized with regard to
properties such as the intestinal permeability and
transport, although rough predictions can be made
from molecular descriptors.14 In this contribution,
therefore, we investigated the in vitro permeability
and transport of a series of HIV-1 PIs that are struc-
tural variants of registered PIs, including indinavir.
This series was chosen because PIs are associated
with poor bioavailability, and therefore there is a need
toidentifymoleculardeterminantsoffeaturessuchas
active and passive drug transport across the intesti-
nal epithelium.15–17
More speciﬁcally, we studied a new class of com-
pounds comprising a shielded, tertiary alcohol as
partofthetransition-statemimickingscaffold.18–21 In
these inhibitors, the polar hydroxyl group may form
intramolecular hydrogen bonds and is well masked
by the surrounding carbon skeleton, features often
used to improve the membrane permeation ability
of organic compounds.22–24 In the reported P1  para-
functionalized series, wherein the main difference is
in the length of the carbon core structure and in the
P2 side chain, highly potent inhibitors were obtained
with Ki values below 10nM and cellular half max-
imal effective concentration (EC50) activities below
0.50:M. To our delight, good metabolic stability in
microsome preparations and good Caco-2 cell mem-
brane permeability were recorded for several com-
pounds. However, despite that, low Ki values were
obtained with P1  meta-substituted inhibitors in the
cell-free assays; we could not explain why these com-
pounds were devoid of activity in the cell assay.
Thus, with the intention of investigating this is-
sue, we selected a subset of PI analogues that was
representative of the differing inhibitory potential in
cell-free assays, in comparison with cell assays, and
investigated their permeability in 2/4/A1 and Caco-2
cell monolayers. As the lower activity in the cell as-
says could be due to efﬂux by ABC transporters such
as P-gp, we also investigated their transport in the
secretory direction across Caco-2 cells. Through this
approach, we could both evaluate the performance of
2/4/A1 cells as an alternative cell model for perme-
ability screening and investigate whether the passive
membrane permeability and/or drug efﬂux could ex-
plain the observed reduction of PIs activity in the cell-
based assays. Structural features that alter passive
permeability and efﬂux by ABC transporters could
also be identiﬁed.
MATERIALS AND METHODS
Unless otherwise stated, all culture media and
supplements were purchased from Invitrogen AB
(Liding¨ o, Sweden). Hanks’ balanced salts solution
(HBSS), epidermal growth factor (EGF), insulin-
like growth factor-1, insulin, human transferrin
and selenous acid premix, water-soluble dexam-
ethasone, extracellular matrix (ECM) protein gel,
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
(HEPES), bovine serum albumin (BSA), Triton-X100,
dimethyl sulfoxide (DMSO), and acetonitrile were
purchased from Sigma–Aldrich (Stockholm, Sweden).
[14C] mannitol was purchased from PerkinElmer
Sverige AB, (Upplands V¨ asby, Sweden) and the
phosphate-buffered saline was purchased from
(Medicago, Sweden).
2/4/A1 Cell Culture
2/4/A1 cells were conditionally immortalized with
a pZipSVtsa58 plasmid containing a temperature-
sensitive mutant of the SV40 large T antigen. The
cells were expanded at 33◦Ci nR P M I( R o s w e l l
Park Memorial Institute Medium) 1640 medium
supplemented with 5% fetal calf serum, 2mM L-
glutamine, and 20ng/mL EGF. At passage num-
bers 32 to 45, 2/4/A1 cells were seeded on per-
meable polycarbonate ﬁlter supports (0.45-:m pore
size, 12-mm diameter; Transwell Costar, Sigma–
Aldrich), freshly coated with an ECM protein gel
(16:g/cm2) at a density of 100,000cells/cm2. NCTC-
109, with the following additives, was used for the
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ﬁlter-grown cells: 2mM L-glutamine, 10:M dexam-
ethasone (water soluble), 10mM HEPES, 0.1% BSA,
penicillin (100U/mL), and streptomycin (100:g/mL).
The cells were allowed to grow at 39◦C for 6–7 days
beforethemonolayers wereusedindrugtransportex-
periments. At this time, the cell monolayers used in
this study had a mannitol permeability of less than
6× 10−6 cm/s and a transepithelial electrical resis-
tance (TEER) of more than 35ohm × cm2.
Caco-2 Cell Culture
Caco-2 cells originating from a human colorectal car-
cinoma were obtained from American Type Culture
Collection (Manassas, Virginia) and were cultivated
as described previously in detail.13 In brief, Caco-2
cells were seeded at a density of 330,000cells/cm2
on permeable polycarbonate ﬁlter supports (0.45-:m
pore size, 12-mm diameter; Transwell Costar, Sig-
ma–Aldrich) in Dulbecco’s modiﬁed Eagle’s medium
supplemented with 10% fetal calf serum, 1% Min-
imum Essential Medium nonessential amino acids,
penicillin (100U/mL), and streptomycin (100:g/mL).
Caco-2 cells were used at passage numbers 95
through 105. The Caco-2 cell monolayers were chosen
for transport experiments between 21 and 28 days af-
ter seeding. At this time, the cell monolayers used in
this study had a mannitol permeability of less than
0.3× 10−6 cm/s and a TEER of more than 240ohm ×
cm2.
Integrity Studies
The integrity of the 2/4/A1 and Caco-2 monolayers be-
fore the experiments and after the exposure of each
of the compounds under investigation (observed solu-
bility in HBSS, pH 7.4, >5:M) was determined using
theparacellular markermolecule[14C]mannitol(spe-
ciﬁc activity 2.176GBq/mmol) and by measuring the
TEER, as described elsewhere.13
Each compound was dissolved in DMSO as a 1mM
stock solution. Before the experiments, they were fur-
ther diluted in HBSS containing 25mM HEPES, pH
7.4, to a ﬁnal concentration of 5 :M.
The transepithelial transport of [14C] mannitol
across the epithelial cell monolayer was assessed by
the apparent permeability coefﬁcient, Papp, according
to Eq. (1):
Papp =
1
AC0
dQ
dt
(1)
Q is the amount of [14C] mannitol transported into
the basolateral chamber, t is the elapsed time, A is the
area available to transport (1.131cm2), and C0 is the
initial concentration of [14C] mannitol. The Papp was
expressed in centimeter per second.
The PIs investigated in this study did not affect
the integrity of the 2/4/A1 cell and Caco-2 monolay-
ers, as measured by transepithelial transport of [14C]
mannitol. Thus, [14C] mannitol permeability was not
signiﬁcantly different to control monolayers after in-
cubation with the PIs.
Transport Experiments In 2/4/A1 And Caco-2
Monolayers
The investigation of the transport of the compounds
1–11 and indinavir was performed in accordance with
published protocols,8,13,25 with the modiﬁcation of 1%
BSA being included in all receiver chambers to im-
prove the mass balance.26 Brieﬂy, ﬁlters with mature
2/4/A1 and Caco-2 monolayers were washed with pre-
warmed HBSS, pH 7.4, for 15 min, whereupon the
HBSS was replaced with prewarmed donor solutions
of the compounds under investigation (5–10:M). The
transport experiments were carried out in the apical-
to-basolateral (a–b) direction in the 2/4/A1 mono-
layers and both the apical-to-basolateral (a–b) and
basolateral-to-apical (b–a) directions in Caco-2 mono-
layers. The monolayers were incubated at 37◦C, and
intense orbital stirring (500rpm) was applied to re-
duce the effect of the unstirred water layer adjacent to
the cell monolayers. The donor and receiver compart-
ments were sampled at regular time intervals (gen-
erally 5, 15, and 30min for highly permeable sub-
stances; and 5, 45, and 90min for substances with
intermediate and low permeability). The ﬁnal sam-
pling from the donor chamber was used to calculate
the mass balance of the compound. In general, a mass
balance of 80% was obtained. Donor samples were di-
luted 10 times in HBSS–acetonitrile (33:67, v/v), and
the receiver samples were diluted in two volumes of
acetonitrile. Precipitated BSA was removed by cen-
trifugation at 12,500g at 4◦C for 15min. Thereafter,
additional dilution in HBSS–acetonitrile (33:67, v/v)
was performed when necessary. The samples were an-
alyzed by liquid chromatography–tandem mass spec-
trometry (LC–MS/MS) immediately after the trans-
port experiments.
Permeability (Papp) values (cm/s) were calculated
in accordance with Eq. (2) (which applies to nonsink
conditions), where CR(t) is the time-dependent drug
concentration in the receiver compartment, M is the
amount of drug in the system, VD and VR are the
volumes of the donor and receiver compartments, re-
spectively, A is the surface area of the ﬁlter (cm2), and
t is the time from the start of the interval.27
CR(t) =
M
VD + VR
+

CR,0 −
M
VD + VR

× e
−Papp ×A×

1
VD
+ 1
VR

×t
(2)
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LC–MS/MS Analysis
The analysis of compounds 1–11 and indinavir was
performed on a Thermo Finnigan TSQ Quantum Dis-
covery triple-quadrupole mass spectrometer (Thermo
Scientiﬁc, Waltham, Massachusetts) equipped with
a Finnigan Surveyor autosampler and high perfor-
mance liquid chromatography (HPLC) pump. Chro-
matographicseparationwasperformedonaReproSil-
Pur C8 (50× 3mm 2, 5u) analytical column supplied
by Dr A. Masch. The HPLC was operated at a ﬂow
rate of 200:L/min with two mobile phases (A and
B): A = 0.1% formic acid/5% acetonitrile (v/v) and B
= 0.1% formic acid/100% acetonitrile. Typically, the
following gradients were applied: %B/time (min); 50/
0–2.5, 95/2.5–4, 50/4–7 or 20/0–0.5, 95/0.5–5.5, and
20/5.5–9. The sample injected was 10:L and all sam-
ples contained one volume of sample and two vol-
umes of acetonitrile. The peak areas obtained in the
chromatograms were integrated automatically by the
mass spectrometry software (Xcalibur 1.4, Thermo
Scientiﬁc, Waltham, Massachusetts). The concentra-
tion was calculated from linear regression of standard
samples with Graphpad Prism 4 (Graphpad Software
Inc., La Jolla, California).
Molecular Descriptors
Three-dimensional molecular structures were gener-
ated from SMILES representations for the calcula-
tions of the topological polar surface area (TPSA),
Cl o gP,l o gD, log acid dissociation constant (pKa),
number of rotatable bonds, number of donor atoms
for H bonds, number of acceptor atoms for H bonds,
and other molecular descriptors, using Corina version
3.0 (Molecular Networks, Erlangen, Germany). These
were used as the input for the molecular descriptor
calculation, which was performed with DragonX ver-
sion 1.4 (Talete, Milano, Italy) and ADMETPredictor
version 5.0 (Simulations Plus, Lancaster, California).
For the computational modeling, the compounds in
this investigation were described both in terms of
their entire structures and as consisting of a com-
mon core with two substituents, R1 and R2 (Table
1). Dragon descriptors were calculated for the entire
molecule, and for the substituent positions R1 and R2.
In total, 141 and 282 descriptors were used.
Synthesis And Biological Evaluation Of HIV-1
Protease Inhibitors
The synthesis, characterization, and biological
evaluation (Ki,E C 50) of HIV-1 PIs have been re-
ported previously for compounds 1–4,28 and 5–10,19
(Table 1). The synthesis, characterization, and
biological evaluation of methyl (S)-1-(2-((S)-2-benzyl-
3-((S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-
2-ylamino)-2-hydroxy-3-oxopropyl)-2-(4-(pyridin-2-
yl)benzyl)hydrazinyl)-3,3-dimethyl-1-oxobutan-2-
ylcarbamate (11) are described in the supplementary
information.
Statistics
The permeability results are expressed as the mean
values ± SD of three monolayers. The experiments
were repeated on at least two independent occasions.
One-way analysis of variance was used to compare
the means, and a 95% probability was considered to
be signiﬁcant.
The partial least-squares projection to latent struc-
tures (PLS) analyses were performed in version 12.0
of the Simca-P software (Umetrics AB, Umeå, Swe-
den). The data were mean centered and scaled to unit
variance. A variable selection procedure was applied.
Variables exhibiting low variable importance were re-
moved. The aim of the variable selection was to main-
tain predictivity and to increase the robustness of the
models, as well as to decrease the complexity of the
models and to facilitate interpretation by removing
information that was not directly related to the re-
sponse variable (i.e., noise). The accuracy of the PLS
models was judged by the R2 and the square root of
the variance of the residuals. The models were vali-
dated by fourfold cross-validated R2 (Q2) (see supple-
mentary information). Transport across 2/4/A1 cells
was analyzed and modeled as the square root of the
original Papp values.
RESULTS
The calculated molecular descriptors indicated that
all compounds in the series (1–11 and indinavir)
were uncharged at physiological pH and had rather
high molecular weights (>613.9g/mol), lipophilic-
ities (>3.19), rotatable bonds (>12), and TPSAs
(>120.0Å2), as shown in Table 1. Thus, the compound
series had molecular properties that are generally
considered to be disadvantageous for the membrane
permeability and drug absorption. For instance, only
three of the compounds, including indinavir, did not
violate Lipinski’s rule of ﬁve, whereas permeabil-
ity experiments indicated that all compounds had
intermediate-to-high permeabilities in the absorp-
tive direction in both cell models (Table 1). Further-
more, most compounds had a TPSA of larger than
120–140Å2 (range 120.0–168.5Å2), which was the
value originally proposed the interval in which the
cutoff for orally available drugs should lie.29,30 The
rather high membrane permeability in spite of this
violation can, possibly, be explained by sterical pro-
tection of and/or intramolecular hydrogen bond for-
mation by the tertiary hydroxyl group (which has a
polar surface area of 20Å2) because these effects are
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Table 1. Structures, Molecular Properties, Activity, Permeability, and Efﬂux of the HIV-1 Protease Inhibitors
Papp × 105 (cm/s)b
Compounda R1 R2
MW
(g/mol) ClogP
No. of
Rotatable
Bonds
TPSA
(A2)
Lipinski’s
Rule
Violation Ki (nM)
EC50
(:M) 2/4/A1 Caco-2 (a–b)
Caco-2
(b–a)
Efﬂux
Ratio
1 681.7 4.93 13 140.2 No 2.4 1.1 19.23±1.88 9.78 ± 1.20 24.56 ±0.39 2.5
2 678.9 5.70 14 140.2 Yes 20 0.70 8.23±0.35 8.08 ± 0.66 2.79 ± 0.20 0.3
3 704.9 6.17 15 140.2 Yes 11 >10 3.20±0.25 0.83 ± 0.13 0.25 ± 0.01 0.3
4 735.0 6.86 14 168.5 Yes 3.5 >10 0.41±0.13 0.15 ± 0.01 0.17 ± 0.01 1.1
5 639.7 5.34 14 120.0 Yes 88 >10 24.50±1.50 9.09 ± 0.04 2.63 ± 0.02 0.3
6 619.6 3.53 13 129.2 No 110 >10 12.91±1.00 1.06s ± 0.46 5.80 ± 0.75 5.5
7 655.7 5.55 13 140.2 Yes 480 >10 37.41±4.65 18.79 ± 1.74 19.04 ±1.00 1.0
8 706.8 4.12 18 158.3 Yes 5.1 3.1 4.09±0.27 0.48 ± 0.01 31.25 ±8.97 65
9 710.7 4.96 16 149.1 Yes 860 >10 21.76±0.58 6.81 ± 0.02 5.34 ± 0.38 0.8
10 676.7 4.52 15 149.1 Yes 180 >10 5.73±0.99 0.25 ± 0.01 7.00 ± 1.23 28
11 674.8 4.30 16 162.0 Yes 23 >10 0.38±0.09 0.34 ± 0.04 2.60 ± 0.91 7.6
613.9 3.19 12 118.0 No 0.52 0.041 0.79±0.16 0.43 ± 0.16 3.44 ± 0.45 8.0
Minimum 613.9 3.19 12 120.0 – 0.52 0.041 0.38 0.15 0.17 0.3
Maximum 735.0 6.86 18 168.5 – 860 >10 37.41 18.79 31.25 65
Median 677.8 4.95 14 140.2 – 22 >10 6.98 0.95 4.39 5.6
aThe experimental procedures and characterization have been reported previously in the following references: 1–428, 5–1019 and for the experimental
details for 11, see the supplementary information. The molecular descriptors were calculated as described in Materials and Methods.
bThe permeability coefﬁcients were determined in the apical-to-basolateral (a–b) direction in 2/4/A1 cell monolayers and in the apical-to-basolateral (a–b)
and/or basolateral-to-apical (b–a) direction in Caco-2 cell monolayers, respectively, as described in Materials and Methods. The permeability coefﬁcients are
presented as the mean values ± SD, n = 3.
TPSA, topological polar surface area.
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Figure 1. Transport of HIV-1 protease inhibitors in 2/4/
A1 cell monolayers. The transport was studied in apical-
to-basolateral (a–b) direction as described in Materials and
Methods. BSA (1%) was present in the receiver solutions.
Each bar represents the mean of permeability coefﬁcient
(Papp) ± SD, n = 3.
not accounted by the TPSA or other relevant molecu-
lar descriptors used in this study.
The deﬁnitions of high, intermediate, and low per-
meabilities in the present paper are consistent with
those presented by Matsson et al.,7 illustrating the
reproducibility of these cell models in our laboratory.
Thus, in 2/4/A1 cells, highly permeable compounds
were deﬁned as those having a permeability coefﬁ-
cient of more than 40 × 10−6 cm/s, whereas a per-
meability range of 8–40 × 10−6 cm/s deﬁned com-
pounds with intermediate permeability. Low perme-
able compounds had permeability coefﬁcients of less
than 8 × 10−6 cm/s. The corresponding values for
Caco-2 cells were more than 2 × 10−6 cm/s (high per-
meability), 0.2–2 × 10−6 cm/s (intermediate perme-
ability), and less than 0.2 × 10−6 cm/s (low perme-
ability). Using these criteria, it is clear from Table 1
that the majority of the compounds studied in 2/4/A1
and Caco-2 monolayers were highly permeable.
A closer examination of the permeability data
showed that the passive permeability of the PIs in
2/4/A1 cells covered a range from low to high. Thus,
the Papp values ranged from 3.8 × 10−6 cm/s (com-
pound 11) to 374 × 10−6 cm/s (compound 7), which is
about a 100-fold variation (Table 1; Fig. 1). Surpris-
ingly, no relationship could be observed between the
permeability and activity in the cell assay (EC50).
In compounds 1–4,t h eR 1 substituent was the
indanol used in this position in indinavir, whereas
the R2 substituent was varied in size in the order
bromo- <, phenyl- < styrene- < benzothiophene-. In-
terestingly, the permeability decreased with increas-
ing size of the R2 substituent, and the permeability
of the benzothiophene-substituted compound 4 was
47 times lower than that of the bromo-substituted
compound (1) as in turn had 24 times higher than
that of indinavir (Fig. 1).
In compounds 5–10, the bromo substituent was
kept constant in the R2 position, promoting high
permeability as judged from compounds 1–4.I n -
stead, the R1 substituent was varied with the help
of structural motifs taken, at least in part, from reg-
istered PIs. These included the tetrahydrofuryl sub-
stituent in compound 6 (amprenavir), the hydrox-
ymethylphenyl in compound 7 (nelﬁnavir), and the
tert-leucine–N-methyl amide in compounds 10 and 11
(atazanavir). In compound 11, in addition, the R1 sub-
stituent was altered to 2-pyridyl (atazanavir). In com-
pounds 8 and 9, valine–N-methoxyethyl amide and
phenylalanine–N-methyl amide were used as R1 sub-
stituents, forming a small series with side chains of
neutral amino acids together with compound 10.I n
compound 5, a benzyl group was used as the sub-
stituent in position R1.
Although the passive permeabilities of com-
pounds 5–10 were high, compound 11, which mim-
ics atazanavir also in the R2 position (2-pyridyl-
substituent), had a low passive permeability, giving
further support to the idea that the smaller bromo
substituent in the R2 position promotes high perme-
ability. Thus, for compounds 5–10, the permeabili-
ties ranged from 41 × 10−6 cm/s (compound 8)t o
374 × 10−6 cm/s (compound 7), corresponding to a
ninefold variation. Interestingly, compound 7 shares
thehydroxymethylphenylsubstituentwithnelﬁnavir,
a PI with good absorption, but with a highly vari-
able bioavailability.31 The permeability of compound
9 carrying the phenylalanine–N-methyl amide sub-
stituent was approximately four times higher than
those of compounds 8 (valine–N-methoxyethyl amide)
and 10 (tert-leucine–N-methyl amide). Clearly, the
larger aromatic phenylalanine side chain affords a
higher permeability.
Because the discrepancy in the potency of the
PIs between the cell-free and the cell assays could
not be related to differences in passive permeabil-
ity, we investigated the bidirectional permeability
in Caco-2 cells (Table 1, Fig. 2). This approach al-
lows the identiﬁcation of active transport mecha-
nisms, in particular, by ABC transporters such as
P-gp.13,32 From the results in Caco-2 cells, a partly
different picture emerges. Although the permeabil-
ity ranking was qualitatively comparable to that
obtained in 2/4/A1 cells, several of the compounds
had large efﬂux components, resulting in low perme-
abilities in the absorptive (a–b) direction. For com-
pounds 2 and 5, a possible active uptake process was
observed.
As in 2/4/A1 cells, indinavir displayed a relatively
low permeability in the absorptive direction, whereas
the permeability in the reverse secretory direction
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Figure 2. Transport of HIV-1 protease inhibitors in Caco-
2 cell monolayers. The transport was studied in apical-
to-basolateral (a–b) and basolateral-to-apical (b–a) direc-
tions as described in Materials and Methods. BSA (1%) was
present in the receiver solutions. Each bar represents the
mean of permeability coefﬁcient (Papp) ± SD, n = 3.
was eight times higher, which is related to the fact
that indinavir is a substrate of P-gp, and is in agree-
ment with the published data.32 In the indanol series,
a signiﬁcant efﬂux was also observed for compound 1,
which is the most likely reason for the permeability in
the absorptive direction for this compound being half
that observed in the 2/4/A1 cells, lacking functional
P-gp. In contrast, compound 4, with the benzothio-
phene substituent in the R2 position, did not exhibit a
higher permeability in the secretory direction. It did,
however, have the lowest permeability of compounds
1–4, supporting the observation in the 2/4/A1 cells
that R2 substitution with the bulky benzothiophene
reduces the permeability.
For compounds 5–11, the highest efﬂux ratios
were observed for the tert-leucine–N-methyl amide
R1-substituted compounds, compounds 10 and 11,
and in particular, the valine–N-methoxyethyl amide-
substituted compound, compound 8, the latter ob-
taining and efﬂux ratio of 65. This is in sharp con-
trast to the highly permeable compound 9, carrying
the phenylalanine–N-methyl amide, for which no ef-
ﬂux could be observed. This ﬁnding is in agreement
with the literature, which indicates that rather small
structural changes switch a P-gp substrate to form a
nonsubstrate.33,34 As in the 2/4/A1 studies, in addi-
tion to compound 9, the highest permeabilities in the
absorptive direction were observed for compounds 5
and 7, that is, the two compounds with the smallest
aromaticsubstituentsintheR1 position.Ofparticular
interest is the fact that compound 7 did not show any
efﬂux at all. As for the passive permeability data, the
observed differences in ABC transporter-mediated ef-
ﬂux in Caco-2 cells could not explain the discrepancy
in potency in the cell-free and cellular assays for the
PI series.
DISCUSSION
At the onset of this study, we wanted to investigate
whether 2/4/A1 cell monolayers offer a suitable model
for studies of passive drug transport in drug discov-
ery and, more speciﬁcally, for ranking of structural
leads according to their permeability. For this pur-
pose,weusedaseriesofHIV-1PIsbecausethesecom-
pounds present complex pharmacokinetic issues, and
limited information is available regarding their struc-
ture–permeability and structure–efﬂux properties. In
addition, compounds from the selected PI series dis-
played a large discrepancy in the inhibitory potential
between the cell-free activity assay, wherein many
compounds were active in the nanomolar range, and
theactivityinacellularassay,whereinthePIneedsto
permeate the cell membrane prior to reaching its tar-
get and wherein the compounds could be inactive in
concentrations up to 10:M. Because the compounds
were considered to have good to acceptable metabolic
stability,18 we speculated that permeability and efﬂux
studies could explain this issue.
Our results clearly indicate that permeability ex-
periments in 2/4/A1 cell monolayers differentiate be-
tween passively transported compounds with phar-
macokinetic liabilities, as exempliﬁed by the HIV-1
PIs. Advantages of 2/4/A1 cells include a tight junc-
tion pore distribution that corresponds better with
those in the human small intestine than Caco-2 cells,5
resulting in quantitatively comparable permeability
data to those obtained in the perfused human in-
testine in conscious humans4,7 and the absence of
measurably active drug transport processes, which
enables studies of passive permeability in isolation
to be made.8 However, comparative efﬂux studies in
Caco-2 cells revealed that some of the highly perme-
able compounds in 2/4/A1 monolayers had signiﬁcant
efﬂux components, reducing the permeability in the
absorptive direction from the high to the intermedi-
ate range. Importantly, because the PIs in this in-
vestigation were uncharged at the physiological pH,
they were not subject to charge-dependent pH traps
such as lysosomal accumulation that may mimic ac-
tive transport.35,36
In drug discovery, an efﬂux ratio larger than two is
often used as a warning of the likelihood of a signiﬁ-
cant drug efﬂux37 and thereby indicating compounds
warranting additional in vitro studies.38 Much larger
ratios were observed for some of the compounds in our
study, pointing to a need for the routine investigation
of ABC transporter-mediated efﬂux of PIs in early
drugdiscovery.Severalconclusionscanbedrawnfrom
this study regarding how the substituent structure
and position can have an impact on the passive per-
meabilityandactiveefﬂux,respectively. First,asmall
substituent, such as a bromo group in the R2 position,
seems to promote high permeability. The larger the
DOI 10.1002/jps JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 100, NO. 9, SEPTEMBER 20113770 LAZOROVA ET AL.
substituent in this position, the lower the permeabil-
ity. Second, the hydroxymethylphenyl substituent in
the R1 position both enhanced the permeability and
limited the efﬂux, at least for the bromo-substituted
compound 7. Another small aromatic benzyl residue
in this position had a similar effect. Third, R1 sub-
stituents containing amide-substituted hydrophobic
amino acids were good substrates for efﬂux trans-
porters in Caco-2 cells, most likely through P-gp. This
resulted in a 23- and ninefold (for leucine- and valine-
containing compounds 10 and 8, respectively) reduc-
tion in permeability in the absorptive direction in
Caco-2 cells in comparison with 2/4/A1 cells. How-
ever, when the amino acid was changed to the aro-
matic phenylalanine, the permeability was increased
and the efﬂux was abolished. The higher uptake of
compounds 3 and 5 observed in the absorptive direc-
tion requires further investigation before an active
mechanism can be conﬁrmed and eventually identi-
ﬁed. Caco-2 cells express several functional uptake
transporters in their apical membranes, but an in-
vestigation of their role in the uptake of compounds 3
and 5 was beyond the scope of this paper.
Thus, for good and for bad, Caco-2 cell monolayers
provide a permeability coefﬁcient that is a mixture
of passive and active transport processes. Although
this may serve as a warning bell for drug efﬂux, as in
this study, it should be pointed out that the variable
expressionoftransportproteinsinCaco-2monolayers
may result in over- or underinterpretation of such
data.39
Partial least-square analysis of the passive per-
meability data in 2/4/A1 cells was also performed to
obtain further information about the structural re-
quirements for high and low permeability (see sup-
plementary information, S2). Two models were built:
Model 1 is based on descriptors calculated for the
entire molecule and model 2 is based on descriptors
for the substituent positions R1 and R2, respectively.
Model 2 was somewhat more predictive, as judged
by the reported Q2 values. Model 2 was composed
of two latent variables obtained from nine descrip-
tors with a signiﬁcant statistical quality and a cross-
validated Q2 value of 0.88. The model supported the
analysis performed above. Properties related to the
aromatic character of the R1 substituent, aromatic
ratio, and number of aromatic bonds were important
for enhancing the transport across the 2/4/A1 cells.
The R2 substituent should be as small as possible to
promote transport across the cells, as indicated by
variables such as the “number of non-H atoms” and
the “number of bonds”. This was further manifested
by the negative coefﬁcients for all the descriptors of
this substituent (R2). Modeling of efﬂux was not per-
formed because this response was not “pure,” as the
contributionofvarioustransportpathwayscouldvary
from one compound to another. Computational mod-
eling of P-gp interactions is possible using other sys-
tems, wherein the transport protein is overexpressed
and the expression of endogenous transporters is kept
at background levels.40
Our investigation did not provide an explanation
for the discrepancy in the PI activity between the
cell-free assays and the cellular ones. Initially, we in-
vestigated drug uptake in the MT4 cell line used in
the cellular anti-HIV activity assay. Unfortunately,
the results were not conclusive with regard to posi-
tive controls for P-gp transport (data not shown), and
we therefore turned to cell systems that perform reli-
ably in our laboratory. However, our hypothesis that
variation in membrane permeability or active drug
efﬂux in intestinal epithelial monolayers could pro-
vide clues about the different results in the efﬁcacy
assays turned out to be false. Recent studies indicate
that there are signiﬁcant differences in the transport
protein expression in various cell lines used in drug
discovery.41 Furthermore, theexpressionofefﬂuxpro-
teins in HIV-1-infected MT4 cells used in the cellular
assay of PI activity could be quite different from that
in uninfected MT4 cells and in the Caco-2 cells used in
the present study. In addition, the nonspeciﬁc binding
of the PIs in HIV-infected cells may be different from
that in healthy cells. It would therefore be interest-
ing to study the transporter expression and function
of HIV-infected MT4 cells, but such studies were out
of the scope of the present study. Nevertheless, our
investigation provided important insights into struc-
tural features inﬂuencing the active efﬂux and pas-
sive transport of the PIs and, hopefully, these results
can be used to improve the membrane permeability
and to reduce the efﬂux of new series of HIV PIs.
CONCLUSIONS
2/4/A1 cells ranked passive permeability in a broad
range that allowed the identiﬁcation of structural
elements that either enhanced or reduced the pas-
sive permeability of the investigated series of HIV
PIs. Thus, in particular, a small aromatic R1 sub-
stituent and a small (bromo-) R2 substituent were re-
lated to a high permeability. Similarly, bidirectional
studies in Caco-2 cells associated amide-substituted
smallneutralhydrophobicaminoacids,suchasvaline
and leucine, in the R1 position with enhanced efﬂux,
whereas the corresponding phenyl-N-methyl amide
was found to enhance permeability and to abolish ef-
ﬂux. We hope that these ﬁndings will be useful for the
search for HIV-1 PIs with improved pharmacokinetic
and dynamic properties.
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